-
How MHRA monitors the impact of regulatory action taken.
-
Important to inquire if patients are taking herbal medicines.
-
Cold-chain storage and distribution system now been fully implemented by manufacturer.
-
Use of has led to serious paracetamol overdose in a 6-month-old infant.
-
Overall benefits of long-acting β-agonists (LABAs) in the treatment of chronic obstructive pulmonary disease (COPD) continue to outweigh any risks.
-
Use during breastfeeding
-
Healthcare professionals should consider a dose reduction or discontinuation of mycophenolate mofetil if patients develop pure red cell aplasia.
-
Abacavir should be used in line with current treatment guidelines and with caution in patients with high cardiovascular risk factors.
-
A reminder for those who use topical ketoprofen to avoid direct sunlight, ultraviolet rays, sunbeds or sunlamps.
-
New safety information for intensive monitoring of Erlotinib.
-
Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers.
-
How pharmacists can prevent counterfeits reaching patients.
-
Continued monitoring of medicines with a black triangle status.
-
Use of Antipsychotic may be associated with an increased risk of venous thromboembolic events.
-
These medicines are not first-line options for insomnia.
-
You should take caution when you use NSAIDs in patients with renal impairment or are at risk.
-
Use of aliskiren can cause angioedema, a rare and serious side effect, and or acute renal failure.
-
Mothers who are breastfeeding should not take ACE inhibitors or angiotensin II receptor antagonists in the first few weeks after delivery.
-
Data suggests that long-term use of carbamazepine, phenytoin, primidone, and sodium valproate is associated with decreased bone mineral density that may lead to osteopenia, osteoporosis, and increased fractures.
-
High intravenous doses of methylthioninium chloride (methylene blue) should be avoided for patients being treated with serotonergic antidepressants (eg, SSRIs, clomipramine, and venlafaxine).
-
Healthcare professionals may have more responsibility to accurately prescribe an unlicensed medicine or an off-label medicine than when they prescribe a medicine within the terms of its licence.
-
Advice on how to use cough and cold medicines safely for children under 12 years.
-
Updated guidance to use methylphenidateto safely and effectively for attention deficit hyperactivity disorder (ADHD) in children of 6 years or older and adolescents.
-
Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.
-
There have been reports of necrotising and haemorrhagic pancreatitis in people taking exenatide some of which were fatal - stop exenatide treatment if pancreatitis is diagnosed.
-
Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents - consider stopping this if symptoms occur.
-
In 2008 MHRA commissioned Ipsos MORI to research the public’s perception of herbal medicines, the findings may help doctors and pharmacists when considering how to advise patients.
-
Toremifene (fareston) is associated with a dose-dependent risk of QT prolongation.
-
Generic piperacillin/tazobactam products have different compatibilities with other medicines compared with tazocin, raising a risk of serious medication errors.
-
Severe infusion-related hypersensitivity reactions have occurred in patients receiving temsirolimus.
-
The European Medicines Agency (EMA) has concluded that oral fluoroquinolone norfloxacin (Utinor) shouldn't be used to treat acute or chronic, complicated pyelonephritis.
-
Toxic effects can occur with nitrous oxide especially with prolonged use.
-
New warnings and contraindications for ergot-derived dopamine agonists due to risk of fibrosis associated with chronic use.
-
Use the central alerting system to view and search new alerts, as well as past alerts that were issued through the public health link and safety alert broadcast system.
-
MHRA has received reports of unintentional overdose of fentanyl due to dosing errors, accidental exposure, and exposure of the patch to a heat source.
-
Patients with cancer who received recombinant human erythropoietins in clinical trials had an increased risk of tumour progression and reduced overall survival compared with study controls.
-
Antiepileptic treatment is associated with a small risk of suicidal thoughts and behaviour.
-
Do not prescribe etoricoxib to patients whose blood pressure is persistently above 140/90 mmHg and inadequately controlled.
-
Clinical trial results suggest an increased risk of atrial fibrillation for zoledronic acid (Aclasta▼), pamidronic acid, and possibly for alendronic acid, although the balance-risk remains favourable for bisphosphonates.
-
Licensed doses and differences in potency between different inhaled corticosteroids; advice for use with spacer device.
-
Do not prescribe ergots to patients who have had fibrosis in the heart, lungs, or abdomen.
-
Updated information on supply and clinical advice on enoxaparin (Clexane) pre-filled syringes, contaminated with over-sulphated-chondroitin sulphate (OSCS).
-
Nicorandil is associated with a risk of gastrointestinal ulceration including perianal ulceration.
-
Healthcare professionals should monitor the use and safety of antiretroviral drugs for the treatment of HIV as they are advanced.
-
Most herbal medicines on the UK market are currently unlicensed products and it is difficult for consumers or healthcare professionals to identify which products are manufactured to acceptable standards with reliable product…
-
Latest evidence suggests long-term use of combined oral contraceptives or progestogen-only injectable contraceptives is associated with a small increased risk of cervical cancer.
-
New study shows use of oral contraceptives reduces risk of ovarian cancer.
-
Summary report on the risk of suicidal thoughts and behaviour related to antidepressants.
-
Updated guidance on the supply and administration of Botox, Vistabel, Dysport, and other injectable medicines used in cosmetic procedures.
-
Patients who take telbivudine and pegylated interferon are at increased risk of peripheral neuropathy and should stop taking both medicines if symptoms occur.